Delinia
Delinia is a biotechnology company developing novel therapeutics for the treatment of autoimmune diseases. Delinia’s lead program is a molecule that potentiates and expands Regulatory T Cells (Tregs), powerful immune cells that are critical to maintaining self-tolerance and immune system homeostasis. Tregs are critically important immune regulatory cells in the pathophysiology of cancer and autoimmune disease. Delinia was acquired by Celgene Corporation.
Sector
Biopharmaceuticals
Strategy
Status
Exit
Website
Acquired by Celgene
SofinnovaCapital
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
SofinnovaMD Start
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
SofinnovaDigital Medicine
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.